INDIAN PHARMACEUTICAL INDUSTRY: A VISION WITH ITS STRENGTH AND WEAKNESS Dr. A. SELVARAJ* ABSTRACT The future of Indian pharmaceutical sector looks extremely positive. Indian pharma companies are vying for the branded generic drug space to register their global presence. Several Indian pharmaceutical companies have acquired companies in the US and Europe and many others are raising funds to do so. The Indian Pharmaceutical industry
Premium Pharmaceutical industry Pharmacology Generic drug
Merge che rs & Ac AstraZ eneca Sapom p Wohnb au quisiti J&J Ardea Bioscie n ons of Abbott ces the Top 20 in th Eli Lilly Astra T ech Bayer Synthe s Novex el uest Pirama Acclare l nt Couga Solvay r Mento OMRIX Conor Medsy s Talecri s ICOS TheraS Abbott Invern es Medtec s h ALZA BASF Bayer Foods IVAX SS AG a ca Centoc or ix 20 nco Medise Anima 60 0 20 40 Pharm a Delta P harma g Ops h BU STEAG Vaccin e Man. Plant FH Fau lding BMS O US&Ca
Premium Pharmaceutical industry Mergers and acquisitions Novartis
------------------------------------------------- Fundamental Analysis Fundamental analysis is a technique that attempts to determine a security’s value by focusing on underlying factors that affect a company ’s actual business and its future prospects. On a broader scope‚ you can perform fundamental analysis on industries or the economy as a whole. The term simply refers to the analysis of the economic well-being of a financial entity as opposed to only its price movements. Fundamental analysis
Premium Generic drug Pharmaceutical industry Financial ratios
regards the price‚ structure‚ or timeline of the deal? A cabinet example on the importance of due diligence is the deal between Dai-Ichi Sankyo and Ranbaxy. As Dai-Ichi failed to conduct adequate due diligence‚ they ended up suffering huge losses. The reason being that they were never fully aware of the extent of the Food and Drug (FDA) Investigation into Ranbaxy when it was asked to shut down all its pending and future drug applications from its Ponta Sahib plant in 2009. (Source: https://blog.ipleaders
Premium Management Balance sheet Generally Accepted Accounting Principles
EXECUTIVE SUMMARY Global Pharma Industry is likely to grow at a CAGR of 5% to US $ 1 Trillion by 2013 The Pharmaceuticals Industry in India is the world’s 3 largest in terms of volume and stands 14th in terms of sale. Domestic pharma sector benefitted from increased thrust on Rural Health through bigger budgetary allocations in the Budget of 2009-10 According to PWC in 2010‚ India joined the league of Top 10 global pharmaceutical markets in terms of sales by 2020 with value reaching
Premium Pharmaceutical industry Generic drug
efficacy and tolerability‚ but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations‚ as well as offering an improved safety profile. DS-5565 is an oral‚ small-molecule analgesic being developed by Daiichi Sankyo for the treatment of PDN. It is a voltage-dependent calcium channel alpha-2-delta ligand‚ meaning that it has a mechanism of action similar to Lyrica and gabapentin‚ and reduces pain through the inhibition of calcium channelassociated currents
Premium Pain
Sri Sharada Institute Of Indian Management - Research (A unit of Sri Sringeri Sharada Peetham‚ Sringeri) Approved by AICTE Plot No. 7‚ Phase-II‚ Institutional Area‚ Behind the Grand Hotel‚ Vasant Kunj‚ New Delhi – 110070 Tel.: 2612409090 / 91; Fax: 26124092 E-mail: administration@srisim.org; Website: www.srisim.org DEVELOPMENT DAY PROJECT REPORT STRATEGIC ALLIANCE IN INDIAN PHARMACEUTICAL INDUSTRY Submitted by: | Name: Jagriti Singh (20090123) Amardeep Tomar(20090106)
Premium Pharmaceutical industry Pharmacology Drug discovery
A project report on INTER COMPANY ANALYSIS Analysis of Pharmaceutical Industry in the Indian environment and comparative analysis among Ranbaxy Laboratories Ltd. and Cipla Ltd. Under the guidance of Prof P. Madhavan Visiting Professor‚ IIM Rohtak Undertaken by Ashwani Kumar Atif Aslam Dhiraj Rishiraj Sisodiya Shashi Singh pgp03.016 pgp03.017 pgp03.019 pgp03.054 pgp03.053 This project report is submitted as a partial requirement for the fulfilment of the Business Analysis and Valuation
Premium Financial ratios Financial ratio Generic drug
STRATEGIC ALLIANCE ASSIGNMENT On Eli Lilly’s Strategic Alliance Management Function SUBMITTED TO: Prof: Muqbil Burhan SUBMITTED BY: Smiti Rastogi 063053 IMG-6 FORE SCHOOL OF MANAGEMENT INTRODUCTION Eli Lilly and Company has been in business for more than 135 years. The global‚ research-based company was founded in May 1876 by Colonel Eli Lilly in Indianapolis‚ Ind.‚ in the Midwestern section of the United States. He was a 38-year-old pharmaceutical chemist and a veteran
Premium Eli Lilly and Company Insulin
A report on the growing market of mergers‚ acquisitions‚ and restructurings in the corporate world. Roll No – A3906407G43 Enrolment No – A3906407403 Sudhanshu Gupta | Final Report Guided By – Mrs. Kavitha Menon July 21‚ 2008 | CORPORATE RESTRUCTURING | ACKNOWLEDGEMENT I wish to acknowledge my deep gratitude to Mrs. Kavitha Menon for her valuable guidance‚ wise suggestions‚ mellow criticism & above all unflinching moral support throughout the work. I wish to thank all the library
Premium Mergers and acquisitions